CHP
SIOX

Cable Hill Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cable Hill Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,000
Closed -$37K – 97
2020
Q1 		$37K Buy
+15,000
New +$54.2K 0.01% 85
2017
Q4 		– Sell
-34
Closed -$2K – 1044
2017
Q3 		$2K Buy
+34
New +$5.74K ﹤0.01% 948

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cable Hill Partners's SIOX Position: Q2 2020 in Review

Cable Hill Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2020, closing a stake of 15,000 shares — an estimated $37K sold.

Cable Hill Partners first reported a position in SIOX in Q3 2017 and held it in 2 quarters. The position peaked at $37K in Q1 2020. 40 funds tracked by Wall St. Rank hold SIOX as of Q2 2020.

  • Cable Hill Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Cable Hill Partners sold 15,000 Sio Gene Therapies Inc. Common Stock shares in Q2 2020, an estimated $37K.
  • Cable Hill Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Cable Hill Partners's Sio Gene Therapies Inc. Common Stock position peaked at $37K in Q1 2020.
  • 40 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2020.

Based on Cable Hill Partners's 13F filing for Q2 2020, filed 13 Aug 2020.